We are live on ! Find out more
PP

Paloma Partners Portfolio holdings

AUM $510M
1-Year Est. Return 286.05%
This Fund
S&P 500
This Quarter Est. Return
+3.59%
1 Year Est. Return
+286.05%
3 Year Est. Return
+321.92%
5 Year Est. Return
+284.54%
10 Year Est. Return
+855.7%
AUM
$10.2B
AUM Growth
+$2.21B
Cap. Flow
+$1.91B
Cap. Flow %
18.7%
Top 10 Hldgs %
42.15%
Holding
2,326
New
523
Increased
761
Reduced
552
Closed
381

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$88.6M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$55.2M
3
AMZN icon
Amazon
AMZN
+$50.7M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.4M
5
AAPL icon
Apple
AAPL
+$27.4M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 4.46%
2 Industrials 3.74%
3 Financials 3.69%
4 Healthcare 3.55%
5 Technology 3.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DRRX
1901
DELISTED
DURECT Corp
DRRX
$83K ﹤0.01%
+6,195
New +$79.1K
OSG
1902
DELISTED
Overseas Shipholding Group Inc.
OSG
$82K ﹤0.01%
+21,307
New +$155K
XCO
1903
DELISTED
Exco Resources
XCO
$79K ﹤0.01%
+6,026
New +$96.8K
RCKT icon
1904
Rocket Pharmaceuticals
RCKT
$355M
$76K ﹤0.01%
+3,133
New +$89.4K
TCRT icon
1905
Alaunos Therapeutics
TCRT
$4.71M
$68K ﹤0.01%
85
-182
-68% -$164K
SGMO
1906
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$67K ﹤0.01%
+22,011
New +$80.1K
OSIR
1907
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$66K ﹤0.01%
+13,438
New +$68.8K
FOLD
1908
DELISTED
Amicus Therapeutics
FOLD
$65K ﹤0.01%
+13,100
New +$90.7K
IMDZ
1909
DELISTED
Immune Design Corp.
IMDZ
$63K ﹤0.01%
+11,510
New +$81.3K
QURE icon
1910
uniQure
QURE
$2.66B
$58K ﹤0.01%
+10,395
New +$69.8K
ADVM
1911
DELISTED
Adverum Biotechnologies
ADVM
$55K ﹤0.01%
+1,908
New +$62.4K
RGLS
1912
DELISTED
Regulus Therapeutics
RGLS
$55K ﹤0.01%
+204
New +$66.3K
IMUX icon
1913
Immunic
IMUX
$188M
$54K ﹤0.01%
+31
New +$67.9K
ARC
1914
DELISTED
ARC Document Solutions, Inc.
ARC
$52K ﹤0.01%
+10,270
New +$43K
CXRX
1915
DELISTED
Concordia International Corp. Common Stock
CXRX
$50K ﹤0.01%
+23,748
New +$72.7K
DVAX
1916
DELISTED
Dynavax Technologies
DVAX
$48K ﹤0.01%
+12,220
New +$89.5K
VNCE icon
1917
Vince Holding Corp
VNCE
$78.1M
$47K ﹤0.01%
+1,149
New +$54.8K
CASC
1918
DELISTED
Cascadian Therapeutics, Inc.
CASC
$47K ﹤0.01%
+10,858
New +$70.2K
ECYT
1919
DELISTED
Endocyte, Inc. Common Stock
ECYT
$46K ﹤0.01%
+18,017
New +$51.7K
AT
1920
DELISTED
Atlantic Power Corporation
AT
$44K ﹤0.01%
+17,719
New +$44K
INFI
1921
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$43K ﹤0.01%
+32,171
New +$42K
ALR
1922
DELISTED
AlerisLife Inc
ALR
$38K ﹤0.01%
+1,404
New +$37.3K
CLDX icon
1923
Celldex Therapeutics
CLDX
$2.81B
$37K ﹤0.01%
+688
New +$39.1K
VBIV
1924
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$33K ﹤0.01%
+355
New +$33.9K
AGPU
1925
Axe Compute Inc
AGPU
$82M
$32K ﹤0.01%
+4
New +$36.9K

Similar funds

Paloma Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Paloma Partners held 2,326 positions worth $10.2B, up 28% from $7.99B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Paloma Partners deployed $1.91B of net new capital in Q4 2016, opening 523 new positions and adding to 761 existing holdings. Its largest new stake was NXP Semiconductors: 253,000 shares worth $24.8M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 4.5% of assets, up from 3.4% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was KLA, an estimated $30.4M trimmed.

  • Paloma Partners's largest Q4 2016 buy was NXP Semiconductors: 253,000 shares worth $24.8M.
  • Paloma Partners added most to Biogen in Q4 2016, an estimated $88.6M increase.
  • Paloma Partners's biggest Q4 2016 reduction was KLA, cutting an estimated $30.4M.
  • Paloma Partners fully exited St Jude Medical in Q4 2016, selling an estimated $13.5M.
  • Paloma Partners's ten largest holdings make up 42% of its $10.2B portfolio in Q4 2016.
  • Paloma Partners opened 523 new positions and closed 381 in Q4 2016.
  • Paloma Partners's portfolio value rose 28% quarter-over-quarter to $10.2B.

Based on Paloma Partners's 13F filing for Q4 2016, filed 14 Feb 2017.